Filing Details

Accession Number:
0000899243-20-008490
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-03-16 17:13:32
Reporting Period:
2020-03-16
Accepted Time:
2020-03-16 17:13:32
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1672619 Imara Inc. IMRA Pharmaceutical Preparations (2834) 811523849
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1734389 Mark Chin 20 Berkeley Square
Mayfair, London X0 W1J 6EQ
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-03-16 1,367,058 $0.00 1,367,058 No 4 C Indirect By entities affiliated with Arix Bioscience plc
Common Stock Acquisiton 2020-03-16 187,500 $16.00 1,554,558 No 4 P Indirect By entities affiliated with Arix Bioscience plc
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect By entities affiliated with Arix Bioscience plc
No 4 P Indirect By entities affiliated with Arix Bioscience plc
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series B Preferred Stock Disposition 2020-03-16 8,611,110 $0.00 1,367,058 $0.00
Common Stock Stock Option (right to buy) Acquisiton 2020-03-16 15,457 $0.00 15,457 $16.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
15,457 2030-03-15 No 4 A Direct
Footnotes
  1. On March 16, 2020, the Issuer's Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
  2. These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
  3. The reporting person is a member of the Investment Committee of Arix and shares voting and dispositive power over the shares held by Arix. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of all of the reported shares for purposes of Section 16 or any other purpose.
  4. The option vests in three equal installments on March 16, 2021, 2022 and 2023.